Liver fibrosis markers of nonalcoholic steatohepatitis

World Journal of Gastroenterology

Volumn 21, Issue 24, 2015, Pages 7427-7435

  Enomoto, Hirayuki ^a   Bando, Yukihiro ^b   Nakamura, Hideji ^c   Nishiguchi, Shuhei ^a   Koga, Masafumi ^d  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b FUKUI KEN SAISEIKAI HOSPITAL   (Japan)

^c NISSAY HOSPITAL   (Japan)

^d KAWASAKI MUNICIPAL HOSPITAL   (Japan)

Author keywords

Glycated albumin; Glycated hemoglobin; Liver fibrosis; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; GLYCOSYLATED ALBUMIN; GLYCOSYLATED PROTEIN; HEMOGLOBIN A1C; HYALURONIC ACID; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRIACYLGLYCEROL;

ALCOHOL LIVER DISEASE; ARTICLE; CLINICAL FEATURE; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GLYCOBIOLOGY; HEPATITIS B; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION; NONALCOHOLIC FATTY LIVER; OBESITY; PORTAL HYPERTENSION; PREDICTIVE VALUE; PROGNOSIS; PROTEIN GLYCOSYLATION; THROMBOCYTE COUNT; BIOPSY; BLOOD; COMPLICATION; DISEASE COURSE; LIVER; LIVER CIRRHOSIS; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

BIOMARKERS; BIOPSY; DISEASE PROGRESSION; HUMANS; LIVER; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 84936818548     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i24.7427     Document Type: Article

References (74)

1. Caldwell SH, Argo CK. Non-alcoholic fatty liver disease and nutrition. In: Dooley JS, Lok AS, Burroughs AK, Heathcote EJ, editors. Sherlock's Diseases of the liver and biliary system. 12th ed. Oxford: Blackwell Sci Pub, 2011:546-567
2. Teli MR, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995;346:987-990 [PMID: 7475591 DOI: 10.1016/S0140-6736 (95) 91685-7]
3. Naveau S, Raynard B, Ratziu V, Abella A, Imbert-Bismut F, Messous D, Beuzen F, Capron F, Thabut D, Munteanu M, Chaput JC, Poynard T. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 2005;3:167-174 [PMID: 15704051 DOI: 10.1016/S1542-3565 (04) 00625-1]
4. Zelman S. The liver in obesity. AMA Arch Intern Med 1952;90:141-156 [PMID: 14943295]
5. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438 [PMID: 7382552]
6. Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis 1986;8:283-298 [PMID: 3086934]
7. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-2023 [PMID: 22488764]
8. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-873 [PMID: 17006923]
9. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010;53:372-384 [PMID: 20494470]
10. Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, Lonardo A. From NAFLD in clinical practice to answers from guidelines. J Hepatol 2013;59:859-871 [PMID: 23751754 DOI: 10.1016/j.jhep. 2013.05.044]
11. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology 2009;49:1017-1044 [PMID: 19243014 DOI: 10.1002/hep. 22742]
12. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449-1457 [PMID: 14647056 DOI: 10.1016/j.hep. 2003.09.022]
13. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR, Schiff ER. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614-2618 [PMID: 12385448 DOI: 10.1111/j.1572-0241.2002.06038.x]
14. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, Ziol M, Poulet B, Kazemi F, Beaugrand M, Palau R. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003;29:1705-1713 [PMID: 14698338 DOI: 10.1016/j.ultrasmedbio.2003.07.001]
15. Friedrich-Rust M, Ong MF, Herrmann E, Dries V, Samaras P, Zeuzem S, Sarrazin C. Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. AJR Am J Roentgenol 2007;188:758-764 [PMID: 17312065 DOI: 10.2214/AJR.06.0322]
16. Friedrich-Rust M, Wunder K, Kriener S, Sotoudeh F, Richter S, Bojunga J, Herrmann E, Poynard T, Dietrich CF, Vermehren J, Zeuzem S, Sarrazin C. Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology 2009;252:595-604 [PMID: 19703889 DOI: 10.1148/radiol.2523081928]
17. Sporea I, Sirli R, Popescu A, Danilã M. Acoustic Radiation Force Impulse (ARFI) - a new modality for the evaluation of liver fibrosis. Med Ultrason 2010;12:26-31 [PMID: 21165451]
18. Martínez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology 2011;53:325-335 [PMID: 21254180 DOI: 10.1002/hep. 24013]
19. Patel K, Shackel NA. Current status of fibrosis markers. Curr Opin Gastroenterol 2014;30:253-259 [PMID: 24671009 DOI: 10.1097/MOG.0000000000000059]
20. Sharma S, Khalili K, Nguyen GC. Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol 2014;20:16820-16830 [PMID: 25492996]
21. Guéchot J, Poupon RE, Poupon R. Serum hyaluronan as a marker of liver fibrosis. J Hepatol 1995;22:103-106 [PMID: 7665843]
22. Gabrielli GB, Corrocher R. Hepatic fibrosis and its serum markers: a review. Dig Dis 1991;9:303-316 [PMID: 1752069]
23. Kajihara M, Okazaki Y, Kato S, Ishii H, Kawakami Y, Ikeda Y, Kuwana M. Evaluation of platelet kinetics in patients with liver cirrhosis: similarity to idiopathic thrombocytopenic purpura. J Gastroenterol Hepatol 2007;22:112-118 [PMID: 17201890]
24. Fontana RJ, Lok AS. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 2002;36:S57-S64 [PMID: 12407577]
25. Giannini E, Botta F, Fasoli A, Ceppa P, Risso D, Lantieri PB, Celle G, Testa R. Progressive liver functional impairment is associated with an increase in AST/ALT ratio. Dig Dis Sci 1999;44:1249-1253 [PMID: 10389705]
26. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-1075 [PMID: 11297957 DOI: 10.1016/S0140-6736 (00) 04258-6]
27. Forns X, Ampurdanès S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E, Bruguera M, Sánchez-Tapias JM, Rodés J. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36:986-992 [PMID: 12297848 DOI: 10.1053/jhep. 2002.36128]
28. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-526 [PMID: 12883497 DOI: 10.1053/jhep. 2003.50346]
29. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317-1325 [PMID: 16729309]
30. Sud A, Hui JM, Farrell GC, Bandara P, Kench JG, Fung C, Lin R, Samarasinghe D, Liddle C, McCaughan GW, George J. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 2004;39:1239-1247 [PMID: 15122752]
31. Calès P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konaté A, Gallois Y, Ternisien C, Chevailler A, Lunel F. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005;42:1373-1381 [PMID: 16317693]
32. Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, Everhart JE, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Dienstag JL, Morishima C. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 2005;42:282-292 [PMID: 15986415]
33. Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007;45:297-306 [PMID: 17256741]
34. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127:1704-1713 [PMID: 15578508]
35. Patel K, Gordon SC, Jacobson I, Hézode C, Oh E, Smith KM, Pawlotsky JM, McHutchison JG. Evaluation of a panel of noninvasive serum markers to differentiate mild from moderate-toadvanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004;41:935-942 [PMID: 15582126]
36. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231 [PMID: 11961152]
37. Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2005;25:779-786 [PMID: 15998429 DOI: 10.1111/j.1478-3231.2005.01064.x]
38. Sakugawa H, Nakayoshi T, Kobashigawa K, Yamashiro T, Maeshiro T, Miyagi S, Shiroma J, Toyama A, Nakayoshi T, Kinjo F, Saito A. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2005;11:255-259 [PMID: 15633226]
39. Yoneda M, Fujii H, Sumida Y, Hyogo H, Itoh Y, Ono M, Eguchi Y, Suzuki Y, Aoki N, Kanemasa K, Imajo K, Chayama K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Yoshikawa T, Okanoue T. Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. J Gastroenterol 2011;46:1300-1306 [PMID: 21750883 DOI: 10.1007/s00535-011-0436-4]
40. Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008;47:455-460 [PMID: 18038452 DOI: 10.1002/hep. 21984]
41. Kruger FC, Daniels CR, Kidd M, Swart G, Brundyn K, van Rensburg C, Kotze M. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. S Afr Med J 2011;101:477-480 [PMID: 21920102]
42. Fitzpatrick E, Dhawan A. Noninvasive biomarkers in nonalcoholic fatty liver disease: current status and a glimpse of the future. World J Gastroenterol 2014;20:10851-10863 [PMID: 25152587 DOI: 10.3748/wjg.v20.i31.10851]
43. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009;7:1104-1112 [PMID: 19523535 DOI: 10.1016/j.cgh.2009.05.033]
44. Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, Tahiri M, Munteanu M, Thabut D, Cadranel JF, Le Bail B, de Ledinghen V, Poynard T. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006;6:6 [PMID: 16503961 DOI: 10.1186/1471-230X-6-6]
45. Parkes J, Roderick P, Harris S, Day C, Mutimer D, Collier J, Lombard M, Alexander G, Ramage J, Dusheiko G, Wheatley M, Gough C, Burt A, Rosenberg W. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010;59:1245-1251 [PMID: 20675693 DOI: 10.1136/gut.2009.203166]
46. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-1362 [PMID: 10573511]
47. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100 [PMID: 11438497]
48. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T. Liver fibrosis in overweight patients. Gastroenterology 2000;118:1117-1123 [PMID: 10833486]
49. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846-854 [PMID: 17393509 DOI: 10.1002/hep. 21496]
50. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011;43:617-649 [PMID: 21039302]
51. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57:1441-1447 [PMID: 18390575 DOI: 10.1136/gut.2007.146019]
52. Calès P, Lainé F, Boursier J, Deugnier Y, Moal V, Oberti F, Hunault G, Rousselet MC, Hubert I, Laafi J, Ducluzeaux PH, Lunel F. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 2009;50:165-173 [PMID: 18977552 DOI: 10.1016/j.jhep. 2008.07.035]
53. Sumida Y, Yoneda M, Hyogo H, Yamaguchi K, Ono M, Fujii H, Eguchi Y, Suzuki Y, Imai S, Kanemasa K, Fujita K, Chayama K, Yasui K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Okanoue T. A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol 2011;46:257-268 [PMID: 20842510 DOI: 10.1007/s00535-010-0305-6]
54. Younossi ZM, Page S, Rafiq N, Birerdinc A, Stepanova M, Hossain N, Afendy A, Younoszai Z, Goodman Z, Baranova A. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg 2011;21:431-439 [PMID: 20532833 DOI: 10.1007/s11695-010-0204-1]
55. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004;10:429-434 [PMID: 15152612]
56. Vanderschaeghe D, Laroy W, Sablon E, Halfon P, Van Hecke A, Delanghe J, Callewaert N. GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics. Mol Cell Proteomics 2009;8:986-994 [PMID: 19181623 DOI: 10.1074/mcp. M800470-MCP200]
57. Ito K, Kuno A, Ikehara Y, Sugiyama M, Saito H, Aoki Y, Matsui T, Imamura M, Korenaga M, Murata K, Masaki N, Tanaka Y, Hige S, Izumi N, Kurosaki M, Nishiguchi S, Sakamoto M, Kage M, Narimatsu H, Mizokami M. LecT-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients. Hepatology 2012;56:1448-1456 [PMID: 22535703 DOI: 10.1002/hep. 25815]
58. Kuno A, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S, Hige S, Sakamoto M, Kage M, Mizokami M, Narimatsu H. A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep 2013;3:1065 [PMID: 23323209 DOI: 10.1038/srep01065]
59. Toshima T, Shirabe K, Ikegami T, Yoshizumi T, Kuno A, Togayachi A, Gotoh M, Narimatsu H, Korenaga M, Mizokami M, Nishie A, Aishima S, Maehara Y. A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA (+)-M2BP), for assessing liver fibrosis. J Gastroenterol 2015;50:76-84 [PMID: 24603981 DOI: 10.1007/s00535-014-0946-y]
60. Abe M, Miyake T, Kuno A, Imai Y, Sawai Y, Hino K, Hara Y, Hige S, Sakamoto M, Yamada G, Kage M, Korenaga M, Hiasa Y, Mizokami M, Narimatsu H. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol 2014; Epub ahead of print [PMID: 25326152]
61. Lis H, Sharon N. Protein glycosylation. Structural and functional aspects. Eur J Biochem 1993;218:1-27 [PMID: 8243456]
62. Rabbani N, Thornalley PJ. Glycation research in amino acids: a place to call home. Amino Acids 2012;42:1087-1096 [PMID: 20981459 DOI: 10.1007/s00726-010-0782-1]
63. Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A. Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N Engl J Med 1976;295:417-420 [PMID: 934240]
64. Bunn HF, Gabbay KH, Gallop PM. The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 1978;200:21-27 [PMID: 635569]
65. Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care 1995;18:440-447 [PMID: 7497851]
66. Dolhofer R, Wieland OH. Glycosylation of serum albumin: elevated glycosyl-albumin in diabetic patients. FEBS Lett 1979;103:282-286 [PMID: 467671]
67. Guthrow CE, Morris MA, Day JF, Thorpe SR, Baynes JW. Enhanced nonenzymatic glucosylation of human serum albumin in diabetes mellitus. Proc Natl Acad Sci USA 1979;76:4258-4261 [PMID: 291961]
68. Koga M. Glycated albumin; clinical usefulness. Clin Chim Acta 2014;433:96-104 [PMID: 24631132 DOI: 10.1016/j.cca.2014.03.001]
69. Koga M, Kasayama S, Kanehara H, Bando Y. CLD (chronic liver diseases)-HbA1C as a suitable indicator for estimation of mean plasma glucose in patients with chronic liver diseases. Diabetes Res Clin Pract 2008;81:258-262 [PMID: 18513821 DOI: 10.1016/j.diabres.2008.04.012]
70. Bando Y, Kanehara H, Toya D, Tanaka N, Kasayama S, Koga M. Association of serum glycated albumin to haemoglobin A1C ratio with hepatic function tests in patients with chronic liver disease. Ann Clin Biochem 2009;46:368-372 [PMID: 19675058 DOI: 10.1258/acb.2009.008231]
71. Aizawa N, Enomoto H, Imanishi H, Saito M, Iwata Y, Tanaka H, Ikeda N, Sakai Y, Takashima T, Iwai T, Moriwaki E, Shimomura S, Iijima H, Nakamura H, Nishiguchi S. Elevation of the glycated albumin to glycated hemoglobin ratio during the progression of hepatitis C virus related liver fibrosis. World J Hepatol 2012;4:11-17 [PMID: 22312451 DOI: 10.4254/wjh.v4.i1.11]
72. Enomoto H, Aizawa N, Nakamura H, Sakai Y, Iwata Y, Tanaka H, Ikeda N, Aoki T, Yuri Y, Yoh K, Hashimoto K, Ishii A, Takashima T, Iwata K, Saito M, Imanishi H, Iijima H, Nishiguchi S. An Increased Ratio of Glycated Albumin to HbA1c Is Associated with the Degree of Liver Fibrosis in Hepatitis B Virus-Positive Patients. Gastroenterol Res Pract 2014;2014:351396 [PMID: 24693282 DOI: 10.1155/2014/351396]
73. Bando Y, Kanehara H, Aoki K, Toya D, Notsumata K, Tanaka N, Enomoto H, Nishiguchi SH, Nakasho K, Nakamura H, Kasayama S, Koga M. The glycated albumin to glycated haemoglobin ratio increases along with the fibrosis stage in non-alcoholic steatohepatitis. Ann Clin Biochem 2012;49:387-390 [PMID: 22715293 DOI: 10.1258/acb.2012.011139]
74. Pearce SG, Thosani NC, Pan JJ. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomark Res 2013;1:7 [PMID: 24252302 DOI: 10.1186/2050-7771-1-7]